Original Article

You have full text access to this OnlineOpen article

Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer†

Results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel

  1. Tomasz M. Beer MD1,‡,*,
  2. Christopher W. Ryan MD1,
  3. Peter M. Venner MD2,
  4. Daniel P. Petrylak MD3,
  5. Gurkamal S. Chatta MD4,
  6. J. Dean Ruether MD5,
  7. Kim N. Chi MD6,
  8. James Young MS7,
  9. W. David Henner MD, PhD7

Article first published online: 25 OCT 2007

DOI: 10.1002/cncr.23163

Issue

Cancer

Cancer

Volume 112, Issue 2, pages 326–330, 15 January 2008

Additional Information

How to Cite

Beer, T. M., Ryan, C. W., Venner, P. M., Petrylak, D. P., Chatta, G. S., Ruether, J. D., Chi, K. N., Young, J. and Henner, W. D. (2008), Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer. Cancer, 112: 326–330. doi: 10.1002/cncr.23163

Author Information

  1. 1

    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon

  2. 2

    Cross Cancer Institute, Alberta Cancer Board, Edmonton, Alberta, Canada

  3. 3

    Division of Hematology and Medical Oncology, Columbia Presbyterian Medical Center, New York, New York

  4. 4

    Pavillion Hellman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania

  5. 5

    Tom Baker Cancer Centre, Alberta Cancer Board, Calgary, Alberta, Canada

  6. 6

    Division of Medical Oncology, University of British Columbia, Cancer Agency-Vancouver Centre, Vancouver, British Columbia, Canada

  7. 7

    Novacea Inc, South San Francisco, California

  1. ‡

    Fax: (503) 494–6197

*Department of Medicine, Oregon Health and Science University, Mail Code CH14R, 3303 SW Bond Avenue, Portland, OR 97239

  1. †

    The Oregon Health and Science University (OHSU) and Dr. Beer have a significant financial interest in Novacea, Inc, a company that may have a commercial interest in the results of this research and technology. This potential conflict was reviewed and a management plan approved by the OHSU Conflict of Interest in Research Committee and the Integrity Program Oversight Council was implemented.The following were participating investigators who are not included among the authors. Canada (Investigators of the Canadian Urologic Oncology Group): Scott Berry (Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario), Piotr Czaykowski (CancerCare Manitoba, Winnipeg, Manitoba), D. Scott Ernst (London Regional Cancer Centre, London, Ontario), Malcolm Moore (Princess Margaret Hospital-University Health Network, Toronto, Ontario), and Fred Saad (Centre Hospitalier de I'Université de Montréal Hôpital Notre-Dame, Montréal, Qué bec). U.S.: Frederick R. Ahmann (University of Arizona Cancer Center, Tucson, AZ), Ari D. Baron (California Pacific Medical Center, San Francisco, CA), William R. Berry (Raleigh Hematology Oncology Clinic, Cary, NC), Maria B. Bishop (Southern Arizona VA Health Care Sustek, Tucson, AZ), James A. Brown (Associates in Oncology/Hematology, Rockville, MD), Michael A. Carducci (The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD), Tarek A. Chidiac (Mid-Ohio Oncology/Hematology, Inc, Columbus, OH), Luis Chu (Oncology Hematology Consultants, Sarasota, FL), Steven L. Davidson (Montgomery Cancer Center, Montgomery, AL), Robert Dreicer (The Cleveland Clinic Foundation, Cleveland, OH), David M. Ellison (Charleston Hematology Oncology, Charleston, SC), Louis Fehrenbacher (Kaiser Permanente Medical Center, Vallejo, CA), Patrick J. Flynn (Metro-Minnesota CCOP, St. Louis Park, MN), Michael S. Gordon (Arizona Cancer Center, Scottsdale, AZ), Leland M. Green (Tower Cancer Research Foundation, Beverly Hills, CA), Ralph J. Hauke (University of Nebraska Medical Center, Omaha, NE), Celestia S. Higano (Seattle Cancer Care Alliance, Seattle, WA), David H. Irwin (Alta Bates Comprehensive Cancer Center, Berkeley, CA), Vahan S. Kassabian (Georgia Oncology, Atlanta, GA), Manish Kohli (Central Arkansas Veterans Healthcare System, Little Rock, AR), Primo N. Lara, Jr (University of California, Davis Cancer Center, Sacramento, CA), Ellis G. Levine (Roswell Park Cancer Institute, Buffalo, NY), Timothy M. Lopez (New Mexico Cancer Center Associates, Santa Fe, NM), Joseph J. Muscato (Missouri Cancer Associates, Columbia, MO), Ira A. Oliff (Midwest Cancer Research Group, Skokie, IL), Ray D. Page (Texas Cancer Care, Fort Worth, TX), Jonathan A. Polikoff (Southern California Permanente Medical Group, San Diego, CA), Mark U. Rarick (Kaiser Permanente Northwest, Portland, OR), Charles H. Redfern (Sharp Health- Care, San Diego, CA), Donald A. Richards (Tyler Cancer Center, Tyler, TX), Mansoor N. Saleh (Georgia Cancer Specialists, Tucker, GA), Michael A. Savin (Texas Cancer Center at Medical City, Dallas, TX), Mark C. Scholz (Prostate Oncology Specialists, Marina Del Rey, CA), Rakesh Singal (University of Miami Hospital and Clinics, Miami, FL), Daniel Vicario (San Diego Cancer Center, Vista, CA), David M. Waterhouse (Oncology Hematology Care, Cincinnati, OH), and Furhan Yunus (University of Tennessee Cancer Institute, Memphis, TN).

Publication History

  1. Issue published online: 4 JAN 2008
  2. Article first published online: 25 OCT 2007
  3. Manuscript Accepted: 13 AUG 2007
  4. Manuscript Revised: 7 AUG 2007
  5. Manuscript Received: 6 JUN 2007

Funded by

  • Aventis and Novacea, Inc.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (109K)

REFERENCES

  • 1
    Petrylak DP,Tangen CM,Hussain MH,Lara PN,Jr,Jones JA,Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513–1520.
  • 2
    Tannock IF,de Wit R,Berry WR,Horti J,Pluzanska A,Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502–1512.
  • 3
    Beer TM,Eilers KM,Garzotto M,Egorin MJ,Lowe BA,Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol. 2003; 21: 123–128.
  • 4
    Beer TM,Garzotto M,Henner WD,Eilers KM,Wersinger EM. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer. 2003; 89: 968–970.
  • 5
    Beer TM,Garzotto M,Henner WD,Eilers KM,Wersinger EM. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer. 2004; 91: 1425–1427.
  • 6
    Beer TM,Ryan CW,Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol. 2007; 25: 669–674.
  • 7
    Beer TM. ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU Int. 2005; 96: 508–513.
    Direct Link:
  • 8
    Bubley GJ,Carducci M,Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999; 17: 3461–3467.
  • 9
    Therasse P,Arbuck SG,Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205–216.
  • 10
    Halabi S,Small EJ,Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003; 21: 1232–1237.
View Full Article (HTML) Get PDF (109K)